Patient P-01649

Synthetic patientNBL-101 · Day 112 · 45–54 · F · baseline S14Open companion preview

Therapy response

Stable

Tolerance

Deteriorating

GI state

Deteriorating

Inflammatory state

Deteriorating

Nutritional resilience

Stable

Discontinuation risk

67%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S14
Day 31 NP-02 recommended — Dietary Support Protocol NP-02
Day 32 Patient accepted — Started NP-02 in the companion
Day 42 GI symptom burden −20% vs expected — Dietary Support Protocol NP-02
Day 48 Tolerance state changed — Unstable → Improving
Day 51 GI-04 recommended — GI Support Protocol GI-04
Day 52 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 52 Patient accepted — Started GI-04 in the companion
Day 60 GI symptom burden −31% vs expected — GI Support Protocol GI-04
Day 66 Tolerance state changed — Unstable → Improving
Day 67 ME-01 recommended — Monitoring Escalation ME-01
Day 68 Patient accepted — Started ME-01 in the companion
Day 71 Deterioration detected before clinical escalation — Monitoring Escalation ME-01

What changed?

Trajectory began diverging from predicted response on Day 52.

Primary contributors, last 14 days

Toxicity+16
Inflammatory activity+9
Treatment adherence-8
GI instability+5
Nutritional resilience-3

What helped?

Dietary Support Protocol NP-02Day 31
Result: symptom burden −20%
GI Support Protocol GI-04Day 51
Result: symptom burden −31%
Monitoring Escalation ME-01Day 67
Result: deterioration detected before clinical escalation

LIFE OS recommendation

Supportive Compound SC-12

66%

probability of meaningful tolerance improvement

284 similar trajectories
81% showed improvement
median effect visible after 6 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Drug metabolism and exposure ↑60
- DNACYP2D6 poor metabolizer → higher exposure
- BloodToxicity index 48
Autonomic recovery ↓45
- WearableResting HR 73 bpm
- Wearable2,505 steps/day
Inflammatory signalling ↑40
- BloodInflammatory load index 49
- WearableHRV 33 ms, trending down
Butyrate / short-chain fatty acid production ↓35
- MicrobiomeButyrate capacity 35/100
Mucosal barrier integrity ↓30
- MicrobiomeAkkermansia low → thinner mucus layer

DNA

Fictional pharmacogenomic panel

CYP2D6 Poor metabolizer
Higher exposure at standard dose
MTHFR C677T
Reduced folate turnover

Microbiome

Shannon diversity 3.1 · butyrate capacity 35/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiNormal
Bacteroides fragilisNormal
Bifidobacterium longumNormal
EnterobacteriaceaeNormal

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 36 ms
Sleep: 7.3 h
Steps: 3,266
Resting HR: 71 bpm

Daily log: GI score 40, nutritional resilience 53, adherence 47.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Keep meals regular; three to four moderate portions spaced through the day
Include a cooked vegetable portion with each main meal
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Log the daily check-in; one line is enough
A 15-minute walk after lunch
Keep the sleep window steady
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
No additional supplements this week
Fictional demo item: continue vitamin D as before

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01678	53%	S14	GI-04	improved	44
P-01611	51%	S14	GI-04	improved	44
P-01635	51%	S02	GI-04	improved	49
P-01663	51%	S14	GI-04	improved	48
P-01323	50%	S14	GI-04	improved	50
P-01518	50%	S14	GI-04	improved	40
P-01543	50%	S14	GI-04	improved	54
P-01574	50%	S14	GI-04	improved	47
P-01674	50%	S14	GI-04	improved	48
P-01603	49%	S14	GI-04	improved	40
P-01365	48%	S14	SC-12	improved	49
P-01431	48%	S14	GI-04	improved	41